PAVmed Inc. Common Stock (PAVM)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-Buffett investor, I start with durable earnings power and a margin of safety. PAVmed fails the first test today. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was only $33,000 while net income was -$5.4M and diluted EPS was -$0.87. For fiscal 2025, revenue was $71,000, net income $401,000, and diluted EPS -$5.63; the positive annual net income is dwarfed by the latest quarterly loss. Free cash flow is -$7.8M, a -43.1% FCF yield on an $18.1M market cap, and FairStock's Altman Z-score of -9.24 signals serious financial distress. FairStock's Piotroski F-score is 3/9. The business has device candidates—CarpX and EsoCheck—but a moat is unproven; $33,000 of quarterly revenue is not commercial validation at scale. The balance sheet has D/E of 0.88 and FairStock's ROCE is -39.69%, so capital is being consumed. Valuation is ambiguous: at the 2026-10-26 close of $2.26, FairStock's P/B is 0.45, which can look cheap, but P/E is -0.13 because there are no positive earnings to capitalize. The computed Lynch category is TURNAROUND, since it returned to profit after a loss within the last three years, yet the latest filings do not show a stable turnaround. I would require several quarters of rising revenue, narrower cash burn, and a cleaner balance sheet before calling this a sound Graham-style value. Price alone is not margin of safety when losses are this large.

In plain English: PAVmed makes medical devices aimed at unmet needs, including carpal tunnel treatment and esophageal screening. The business looks weak right now: revenue is tiny, losses are large, and cash flow is negative. At the 2026-10-26 close of $2.26, the price looks low versus accounting value, but the numbers do not show a strong or consistently profitable business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer